#USA #Robbins Geller #San Diego #Class Action #ADMA Biologics

ADMA Biologics Class Action Lawsuit Overview

On June 11, 2026, Robbins Geller Rudman & Dowd LLP issued a significant alert regarding the ADMA Biologics, Inc. class action lawsuit. This announcement brings forth a vital opportunity for investors who experienced substantial losses while holding ADMA Biologics (NASDAQ: ADMA) stock during the designated class period, from August 9, 2024, to March 25, 2026. The law firm encourages these investors to seek appointment as lead plaintiff in this legal action, aimed at addressing purported violations of the Securities Exchange Act of 1934 by the company and its key executives.

The Allegations

According to the lawsuit, the accusations leveled against ADMA Biologics include making false or misleading statements, as well as failing to disclose critical information pertinent to investors. Key points include allegations that the company engaged in undisclosed related party transactions and employed channel stuffing techniques to create a misleading impression of revenue growth. Furthermore, it is noted that ADMA Biologics allegedly lacked adequate internal controls within its financial reporting processes.

A report released by Culper Research on March 24, 2026, drew attention to what they claimed was the reality behind ADMA Biologics' reported revenue growth, characterizing it as largely fictitious due to the aforementioned practices. This report stated that had the company maintained consistent payment terms, it would have experienced a year-over-year revenue decline rather than the inflated growth numbers reported. The market reacted swiftly, causing the value of ADMA Biologics shares to drop by over 16% following the report's release.

On March 25, ADMA Biologics retaliated with a press release, contesting the claims made by Culper Research, labeling their assertions as speculative and unreliable. However, further negative feedback followed, leading Cantor Fitzgerald to downgrade ADMA Biologics' stock rating based on the ongoing concerns from the report, resulting in even more declines in stock value.

The Path to Becoming a Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, any investor who purchased ADMA Biologics shares within the class period has the right to seek the role of lead plaintiff in this class action lawsuit. The lead plaintiff is typically the individual with the most significant financial interest in the case, and their primary responsibility is to represent other class members throughout the lawsuit. Furthermore, they are entitled to select their preferred legal representation for the case. Importantly, an investor's potential recovery from any future settlement or ruling is not contingent upon their status as lead plaintiff.

This opportunity represents a crucial step for investors who believe they were misled and suffered losses due to ADMA Biologics' alleged actions. Interested parties are advised to ensure their claims are formalized before the deadline of August 10, 2026.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is a highly respected law firm that specializes in securities fraud and shareholder rights litigation. The firm has made significant strides in investor advocacy, being ranked first in the ISS Securities Class Action Services Top 50 Report for the most recoveries in 2025. Over the last five years, Robbins Geller has secured a remarkable $8.4 billion for investors, establishing itself as one of the largest plaintiffs' firms globally.

To learn more about how to file a claim or to find further details about the ongoing ADMA Biologics class action, investors can reach out to Robbins Geller authorities Ken Dolitsky or Michael Albert at their San Diego office or visit their official website.